Podcasts about informing

Informing, entertaining and connecting isolated farmers was a prime goal of the Radio Broadcasting Company, officially incorporated in August 1925 and a forerunner to RNZ. As RNZ celebrates the centenary, Country Life dips back into the archives to bring you some of the well-loved voices and shows from the rural team over the decades. You can find photos and read more about this episode on our webpage, here.With thanks to:Ngā Taonga Sound & VisionMake sure you're following us on your favourite podcast app, so you don't miss new episodes every Friday evening.Want to chat to us or find out more about RNZ Podcasts? Join the RNZ Podcasts Discussion FacebookGo to this episode on rnz.co.nz for more details

In this episode of Euphoric Evolution, Makhosi and Joanna Murphy explore the deep connections between personal growth, entrepreneurship, and the importance of creative expression. Joanna shares her journey from being a competitive athlete to a successful entrepreneur, emphasizing the inner work required to achieve external success. They discuss the significance of embracing the process, setting boundaries, and the power of informing others in relationships. The conversation highlights the need for authenticity and connection in both personal and professional realms, especially in a rapidly changing world.TakeawaysJoanna's journey from athletics to entrepreneurship highlights the importance of inner transformation.Success is often an inside game, requiring self-discovery and growth.Embracing the process rather than focusing solely on outcomes leads to fulfillment.Creative expression enriches life and can positively impact business.Setting clear boundaries is essential for healthy business relationships.Informing others about your process fosters better communication and understanding.Navigating change requires a focus on adding value and serving others.Work can be a vehicle for personal evolution and growth.Authenticity in business leads to deeper connections with clients.Limitations can create freedom and enhance creativity.Support the show

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

Scientists, leaders, and patients discuss the intersection of cutting-edge science and real-world impact. They explore the importance of patient perspectives in shaping medical advancements and how collaboration fuels groundbreaking research. Key scientific achievements in areas like regenerative medicine, cancer therapies, and space biology are highlighted. The group emphasizes the need for scientists to engage more with the public—through social media and media appearances—to help people understand and value the life-changing discoveries in science. Featuring: Catriona Jamieson, M.D., Ph.D. UC San Diego Sandra Dillon Patient Advocate Alexander Khalessi, M.D., M.B.A. UC San Diego Jana Stoudemire Celestial Strategy, LLC Alysson Muotri, Ph.D. UC San Diego Rebecca Moores Philanthropist and Patient Advocate Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40519]

On today's show, Bob discusses the importance of informing others of your thoughts, emotions, and expectations. Focusing on and building attraction in our relationships improves our overall mental wellness and satisfaction with life.   Each episode of Marauder Radio is a roller-coaster ride through the world of mental health and wellness. It's a treasure trove of witty, inspirational rants and satirical takes on the psychological industry.   At the helm of the Whole in the Soul crew is the irreverent and insightful Pirate King, Bob Zima. A licensed clinical professional counselor and graduate of Chicago's famed Player's Workshop of the Second City, Bob combines his expertise with a sharp sense of humor to make healing and counseling both entertaining and educational.   Through his unique perspective, Bob encourages listeners to embrace a mental "cranium-rectum extraction" (you read that right) and start living life with purpose, joy, and a sense of adventure.   Bob uses a variety of show formats, characters and radio effects to entertain and educate.   Check out all of the treasure that Marauder Radio has to offer by visiting https://www. bobzima.com.  

Today's agenda:  The manual of me Cringe corporate speak: take it offline Hot topic: all things start-ups: how to be successful, key traits and how to survive in an evolving organization What is it like working as an HR professional in a start-up? Reactivity vs. proactivity Working in an unpredictable and evolving environment can be an effective way to grow in your career Opportunities to build departments from the ground up RSUs and equity Informing and influencing on the job - it's not for everybody How do HR and all other business professionals, employees and leaders help shape a healthy startup culture? Questions/Comments  Your To-Do List: Grab merch, submit Questions & Comments, and make sure that you're the first to know about our In-Person Meetings (events!) at ⁠https://www.hrbesties.com⁠. Follow your Besties across the socials and check out our resumes here: ⁠https://www.hrbesties.com/about⁠.  Subscribe to the HR Besties Newsletter - ⁠https://hr-besties.beehiiv.com/subscribe⁠ We look forward to seeing you in our next meeting - don't worry, we'll have a hard stop! Yours in Business + Bullsh*t,  Leigh, Jamie & Ashley Follow Bestie Leigh! ⁠https://www.tiktok.com/@hrmanifesto⁠ ⁠https://www.instagram.com/hrmanifesto⁠ ⁠https://www.hrmanifesto.com⁠ Follow Bestie Ashley! ⁠https://www.tiktok.com/@managermethod⁠  ⁠https://www.instagram.com/managermethod⁠ ⁠https://www.linkedin.com/in/ashleyherd/⁠ ⁠https://managermethod.com⁠ Follow Bestie Jamie! ⁠https://www.millennialmisery.com/⁠ Humorous Resources: ⁠Instagram⁠ • ⁠YouTube⁠ • ⁠Threads⁠ • ⁠Facebook⁠ • ⁠X⁠ Millennial Misery: ⁠Instagram⁠ • ⁠Threads⁠ • ⁠Facebook⁠ • ⁠X⁠ Horrendous HR: ⁠Instagram⁠ • ⁠Threads⁠ • ⁠Facebook⁠ Tune in to “HR Besties,” a business, work and management podcast hosted by Leigh Elena Henderson (HRManifesto), Ashley Herd (ManagerMethod) and Jamie Jackson (Humorous_Resources), where we navigate the labyrinth of corporate culture, from cringe corporate speak to toxic leadership. Whether you're in Human Resources or not, corporate or small business, we offer sneak peeks into surviving work, hiring strategies, and making the employee experience better for all. Tune in for real talk on employee engagement, green flags in the workplace, and how to turn red flags into real change. Don't miss our chats about leadership, career coaching, and takes from work travel and watercooler gossip. Get new episodes every Wednesday, follow us on socials for the latest updates, and join us at our virtual happy hours to share your HR stories. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Biological oceanographer John Ryan joins Mongabay's podcast to discuss his team's multiyear study that examined vocalizations of baleen whales, including blue (Balaenoptera musculus), humpback (Megaptera novaeangliae) and fin whales (Balaenoptera physalus), and how this science is critical for understanding their feeding habits, and thus informing their conservation. The study found that these whales' songs rise and fall with their food supply, which provides valuable insights into how changing ocean conditions can affect their health and guide management measures. “Some of the research we did tracking the movement and ecology of blue whales helped our sanctuary [to] act on this long-term concern about ship strikes, and to join a program that is called Protecting Blue Whales and Blue Skies,” the Monterey Bay Aquarium Research Institute (MBARI) researcher says. Subscribe to or follow the Mongabay Newscast wherever you listen to podcasts, from Apple to Spotify, and you can also listen to all episodes here on the Mongabay website. This episode is dedicated to the memory of Mongabay's East Africa editor, Ochieng' Ogodo. Read here about his life, legacy and achievements. Audio credit: Blue and humpback whale calls featured in this episode are courtesy of MBARI and John Ryan. Image credit: A humpback whale dips back beneath the surface of the ocean. Image courtesy of Cristina Mittermeier/SeaLegacy. ------- Timecodes (00:00) Marine heatwaves and their impact (06:33) Analyzing whale songs (12:30) A change in tune (20:13) Interspecies communication? (25:16) The reason behind the heat (27:36) Informing conservation (36:52) Credits

As blood-based Alzheimer's disease (AD) biomarkers emerge, how can they change primary care's role in AD diagnosis? Credit available for this activity expires: 4/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/informing-alzheimers-disease-referral-blood-based-biomarker-2025a10008tl?ecd=bdc_podcast_libsyn_mscpedu

“Together we can build a thriving future for the building industry globally.” Duayne Pearce. I was raised on the smell of sawdust and paint fumes, spending countless hours on building worksites around South East Queensland, with my idol and best mate, my tradie Dad. I fully immersed myself in an industry that I would ultimately find irresistible. It was obvious from the get-go that an ever-present sense of tension between workers, bosses and customers was the way business was done. But more apparent was that money always seemed to be a problem. Nevertheless, leaving school early I jumped in with both feet. I worked hard, became a licensed builder and carpenter, and then reached the dizzying heights of what would appear on the outside to be an incredible success. The cars, the boats, the properties and even the accolades were afforded by our skyrocketing business turnover, but it was all a thin veneer. Underneath, my business was in danger of going bust and I was heading down that familiar rabbit hole of chronic stress, tension and inevitable outcomes of anxiety and depression. Like many contractors before me, I was about to lose everything. My rock bottom thankfully came with a silver lining and the wherewithal to reach out to my wife, friends and my team to try and sort things out. We worked together and took small steps to turn things around but I knew that I needed more help with structure and process. Business Coaches were part of the solution, but my ah-ha moment was realising none of the ones I had engaged understood or had experience in the building industry. That was my light-bulb moment. I'd found my niche and the journey to re-invent and elevate the industry that has always been so important to me, began. Now, with many collaborators and several innovations under my belt, it's my vision to level up the building industry. I'm on a mission to help others who are just like I was, struggling to make a living, working in one of the most important industries in the country. Informing, guiding, training and speaking are the tools of my trade that push for a revolution in the way residential builders and contractors approach their business to thrive. In doing so, we make vital inroads on how this multi-billion dollar industry is perceived positively by homeowner clients, the community and importantly the next generation of contractors choosing it as their own rewarding career. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Stronger Sales Teams, Ben Wright explores the strategic development and application of sales literature in B2B sales management. Addressing the common challenge of content creation and drawing inspiration from the dynamic global sales landscape, Ben outlines key strategies to boost the impact and efficiency of sales teams. This discussion highlights the significance of crafting engaging, informative, and inspiring sales materials to build and sustain a high-performing B2B sales team. Key Takeaways: Introducing customers to your brand through concise and impactful presentation decks can set the stage for deeper client relationships. Detailed and engaging quotation templates are essential for standing out in a saturated market and effectively communicating your offerings. Leveraging capability statements filled with case studies and testimonials can boost credibility and inspire customer confidence. Prominently featuring customer testimonials and successful case studies acts as powerful tools for validating your brand's capability. Utilizing digital signatures and easy-to-read formats can optimize the client experience and streamline administrative processes. Time Stamps: 0:00 Intro 2:35 Types of Sales Materials or Sales Literature That Sales Teams Need 4:49 Engaging the Customers 6:10 Baseline Presentation Deck 13:44 Informing the Customers 18:00 Inspiring Customers 21:00 Recap 22:06 Iron Man Triathlon 22:57 Outro Rate, Review, & Follow If you're liking what you're hearing, make sure you ‘follow' the show wherever you listen to your podcasts…so you never miss an episode! I'd also love to hear what you think, so drop us a review after you close that next deal…tell me what you're liking, and what you want more of so I can look to cover it in a future episode.

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Explore the cutting-edge intersection of space travel, biology, and health. Experts dive into the effects of microgravity and space radiation on mitochondrial function, DNA repair, and liver regeneration, shedding light on the unique challenges astronauts face during long-term missions. The discussion also touches on metabolic health, highlighting the role of diet and new pharmaceutical treatments like GLP-1 agonists in addressing modern-day health concerns. With engaging insights on how space research can inform breakthroughs on Earth, this talk is a must-watch for anyone interested in the future of human health and space exploration. Series: "MIND - Medicine Informing Novel Discoveries" [Health and Medicine] [Science] [Show ID: 40388]

Governor Glenn Youngkin is considering a bill aimed at cracking down on invasive plants. Michael Pope has the story.

With the help of Teacher-Powered Schools, Socol-Moran Partners, Stimpunks, and What School Could Be, we've officially announced our 4th annual virtual Conference to Restore Humanity for July 21-23, focused this year on the Quest for Connection. If you're interested in joining us, tickets start at just 50 bucks and you can find the full lineup at humanrestorationproject.org/conferenceToday I'm joined by Christian Moore-Anderson. And I wanted to have Christian on to talk about the ideas that drive his teaching practice and that he shares in his book, Difference Maker: Enacting systems theory in biology teaching. While that title may seem daunting, Christian's teaching would immediately look and feel to observers like “just good teaching.” But that's just the tip of the iceberg. Informing his theory and practice of teaching is a set of related ideas that I was largely unfamiliar with before encountering it in his book: cybernetics, systems theory, and enactivism. Cybernetics is simply a feedback loop. Just as someone steering a ship adjusts the rudder based on feedback from the ocean, so too does good pedagogy depend on what Christian calls “recursive teaching”, or a constant feedback loop of action, interpretation, and learning between teachers and students. You can connect with Christian on BlueSky @cmooreanderson.bsky.social.Difference Maker: Enacting Systems Theory in Biology Teaching - Christian Moore-AndersonChristian's Recommended Reading:From Being to Doing: The Origins of the Biology of Cognition - Humberto Maturana, Bernhard PörksenThe Pragmatic Turn: Toward Action-Oriented Views in Cognitive Science Edited by Andreas K. Engel, Karl J. Friston and Danica Kragic Understanding Systems: Conversations on Epistemology and Ethics - Heinz von Foerster The Cybernetic Brain: Sketches of Another Future - Andrew Pickering Runaway: Gregory Bateson, the Double Bind, and the Rise of Ecological Consciousness - Anthony Chaney Hosted on Acast. See acast.com/privacy for more information.

TOM'S BIO  On March 5, 2025, Tom Llamas was named as Lester Holt's successor as anchor and managing editor of NBC Nightly News beginning in summer 2025. This episode is a re-released show originally released on October 26, 2023. Tom's life and career are remarkable and he is a master of truth telling and the news media. He is an American journalist who was the weekend anchor for World News Tonight on ABC and is now Senior National Correspondent and anchor for NBC News Now, hosting Top Story with Tom Llamas, as well as substituting occasionally in NBC's Today and NBC Nightly News.  He has won multiple Emmy Awards for "Best Anchor" and "Best Hard News Story as well an Edward R. Murrow award for his coverage of Hurricane Sandy. His first Emmy award was tied to his brilliant reporting on human smuggling and an interdiction at sea with the U.S. Coast Guard.  Llamas career in a nutshell: NBC News Specials Unit, MSNBC political reporting, NBC's WTVJ in Miami, WNBC in New York, NBC News, ABC News as sole weekend anchor and now back at NBC. Tom has covered the most important stories in recent history: The 2020 presidential race,  the immigration crisis from the U.S. border with Mexico contributed, the death of U.S. war hero Senator John McCain, the rescue mission of the 12 Thai boys trapped in a cave, the sentencing of Bill Cosby, the mass shooting at Marjory Stoneman Douglas High School and many others. He has interviewed President Donald Trump, President Volodymyr Zelensky and Venezuelan President Nicolas Maduro.  Llamas was born and raised in Miami after his parents fled from Cuba during the 1960s. He graduated from Loyola University in New Orleans and lives in Manhattan. EPISODE OUTLINE (0:00) - Intro (0:38) - Bio (01:06) - Discovering a talent, nurturing it, developing it; background informs perspective (02:40) - Getting into the business; Telemundo at 15 years old (04:48) - The path, learning the business, starting at the bottom (05:48) - Media changing, citizen journalism; pros and cons, the future (07:25) - Careers in new media, digital distribution, democratizing fame (08:55) - Training as a journalist, ethics, laws, impartiality; 10,000 reps (10:38) - Americans love variety; from burgers to tomato sauce to news (11:42) - A story that sticks out

Today we are interviewing special guests Drass and Mottzy from Drattzy Games, about their upcoming title Alterium Shift! And also talking about all the OTHER cool RPG stuff from this week! Play the Demo and Wishlist Alterium Shift: https://store.steampowered.com/app/1586990/Alterium_Shift/ Join the last push on the Kickstarter! https://www.kickstarter.com/projects/drattzygames/alterium-shift✩ Audio Version ✩ ► https://superderekrpgs.com/hitpoint/ SOCIAL LINKS --------------------------------------------------- ✩ Derek ✩ ►Twitch: https://www.twitch.tv/SuperDerekRPGs►Bluesky: https://bsky.app/profile/superderekrpgs.com ►Youtube: https://www.youtube.com/@SuperDerek ►Discord: https://discord.me/superderek✩ Baku ✩ ►Twitch: https://www.twitch.tv/BakusanOG►Bluesky: https://bsky.app/profile/bakusanog.bsky.social ►Youtube: https://www.youtube.com/WeebSauce ►Discord: https://discord.me/ABC UPCOMING RELEASES --------------------------------------------------- ►Monster Hunter Wildshttps://www.youtube.com/watch?v=a_wNFT4j6qI  ►Suikoden I & II HD Remaster: Gate Rune and Dunan Unification Warshttps://www.youtube.com/watch?v=VIL88ZqQurQ GAME ANNOUNCEMENTS --------------------------------------------------- ►MADO MONOGATARI: Fia and the Wondrous Academy https://www.youtube.com/watch?v=ssV0H0rXIK0 ►Scar-Lead Salvationhttps://www.youtube.com/watch?v=yKwMv6z5ZZ8 ►KinnikuNeko: SUPER MUSCLE CAT https://www.youtube.com/watch?v=l2YZFe0uzNo ►Fuga: Melodies of Steel 3https://www.youtube.com/watch?v=If5Lzf_M9KU ►Yasha: Legends of the Demon Bladehttps://www.youtube.com/watch?v=OZmVEogYGlc ►The Lonesome Guildhttps://www.youtube.com/watch?v=dQWc-2nEqNE ►Pokemon Legends: Z-A https://www.youtube.com/watch?v=M_KNDtKJJ-8  ►Samurai Pizza Cats: Blast from the Past!https://www.youtube.com/watch?v=dgqr6mm6ZuI INDUSTRY NEWS --------------------------------------------------- Square Enix NieR series 15th anniversary live streamhttps://www.youtube.com/watch?v=3FQD3gUBShw TIMESTAMPS--------------------------------------------------- 0:00 Welcome back to HitPoint! 0:01:06 Intro0:01:37 A Long, Long Time Ago0:02:48 Baku, How Are You Doing?0:04:37 Derek, What's going on?Developer Interview:0:05:35 Interview with "Drass" and "Mottz"y from Drattzy Games, Alterium Shift0:07:15 How Did You Come Together?0:12:50 What Have Been the Biggest Challenges So Far?0:17:22 What Is a Popular Game You Dislike?0:20:27 What Are Some of Your Core Design Philosophies for Alterium Shift?0:23:07 Trailer Watch-Along0:26:37 Were Any Changes or Specific Choices Made Because of Derek's Feedback?0:32:13 How Do You Find a Balance Between Implementing Feedback vs. Your Original Vision?0:35:46 What Are Some of Your Primary Inspirations Behind Alterium Shift?0:39:25 How Difficult Is It to Keep Track of the Different Characters with Their Own Stories?0:42:34 Is the Intention to Play the Game Three Times or Shift Between the Characters?0:46:31 How Do You Create Your Games from Pixel Art to 3D Models?0:49:24 What Role Do Sound Design and Music Play in Informing the Atmosphere of Alterium Shift?0:52:07 Could You Discuss Some of the Technical Choices Behind Implementing Map Abilities?0:55:31 How Do You Plan to Balance Early Access with the Kickstarter?0:59:29 How Do You Envision the Transition from Early Access to a Full Game?1:02:43 How Do You Balance Taking Creative Risks with Practical Commercial Considerations?1:07:14 I Heard, Mottzy, That Your Employment Situation Will Change a Little Bit?1:09:31 Your Kickstarter Reached Its Funding Level and the First Stretch Goal?1:12:19 What Was the Catalyst for Making a Whole Bunch of Changes?1:17:14 Will You Also Change the Font?1:19:16 How Have You Made an Agile Development Process Work for You?1:27:26 How Long Do You Suppose You'd Like to Support the Game After Release?1:34:03 What Are Some Other Things You Can Share with Us About Future Projects?1:35:52 What Is Your Taylor Ratio?1:37:10 Is There a Question You Wish Was Asked?1:44:38 RetrospectiveUpcoming Releases This Week:1:46:30 Monster Hunter Wilds1:53:31 Suikoden I & II HD Remaster: Gate Rune and Dunan Unification WarsNew Games Announced:1:59:13 MADO MONOGATARI: Fia and the Wondrous Academy – 20252:02:31 Scar-Lead Salvation – 29 May 20252:04:29 KinnikuNeko: SUPER MUSCLE CAT – Console Release 19 March 20252:06:50 Fuga: Melodies of Steel 3 – 29 May 20252:11:45 Yasha: Legends of the Demon Blade – 24 April 20252:14:30 The Lonesome Guild – Fall 20252:17:20 Pokémon Legends: Z-A – Late 20252:25:47 Samurai Pizza Cats: Blast from the Past! – 2026Industry News:2:29:54 Square Enix NieR Series 15th Anniversary Live StreamResponding to Super Chats & Outro:2:33:42 Responding to Super Chats2:42:23 Outro

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview & Definition of Biomarkers - What are Some Examples of Biomarker Testing - How Biomarker Testing Provides Useful Information for Cancer Treatment - Why the Molecular Portrait of Cancer is so Important - The Role of the Pathologist - Benefits of Biomarker Testing & Precision Medicine - Predicting Response to Treatment - Clinical Trials: How Research Contributes to Your Treatment Options - Key Questions to Ask Your Health Care Team - Guidelines for Preparing for Telehealth Appointments with Your Health Care Team, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Quality-of-Life Concerns - Questions for Our Panel of Experts

Dr. Neeraj Agarwal and Dr. Peter Hoskin discuss key abstracts in GU cancers from the 2025 ASCO Genitourinary Cancers Symposium, including novel therapies in prostate, bladder, and kidney cancer and the impact of combination therapies on patient outcomes. TRANSCSRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program and professor of medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of ASCO Daily News. Today, we'll be discussing practice-informing abstracts and other key advances in GU oncology featured at the 2025 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Peter Hoskin, the chair of this year's ASCO GU Symposium. Dr. Hoskin is a professor in clinical oncology in the University of Manchester and honorary consultant in clinical oncology at the Christie Hospital, Manchester, and University College Hospital London, in the United Kingdom. Our full disclosures are available in the transcript of this episode. Peter, thank you for joining us today. Dr. Peter Hoskin: Thank you so much, Neeraj. I am very pleased to be here. Dr. Neeraj Agarwal: The GU meeting highlighted remarkable advancements across the spectrum of GU malignancies. What stood out to you as the most exciting developments at the ASCO GU Symposium?  Dr. Peter Hoskin: The theme of this year's meeting was "Driving Innovation, Improving Patient Care," and this reflected ASCO GU's incredible milestone in GU cancer research over the years. We were thrilled to welcome almost 6,000 attendees on this occasion from over 70 countries, and most of them were attending in person and not online, although this was a hybrid meeting. Furthermore, we had more than 1,000 abstract submissions. You can imagine then that it fostered fantastic networking opportunities and facilitated valuable knowledge and idea exchanges among experts, trainees, and mentees. So, to start I'd like to come back to you for a second because the first day started with a focus on prostate cancer and some of the key clinical trials. And congratulations to you, Neeraj, on sharing the data from the TALAPRO-2 trial, which we were eagerly awaiting. I'd love to get your thoughts on the data that you presented. Could you tell us more about that trial, Abstract LBA18?  Dr. Neeraj Agarwal: Yes, Peter, I agree with you. It was such an exciting conference overall and thank you for your leadership of this conference. So, let's talk about the TALAPRO-2 trial. First of all, I would like to remind our audience that the combination of talazoparib plus enzalutamide was approved by the U.S. FDA in June 2023 in patients with metastatic castration-resistant prostate cancer harboring HRR gene alterations, after this combination improved the primary endpoint of radiographic progression-free survival compared to enzalutamide alone in the randomized, double-blind, placebo-controlled, multi-cohort phase 3 TALAPRO-2 trial. In the abstract I presented at ASCO GU 2025, we reported the final overall survival data, which was a key alpha-protected secondary endpoint in cohort 1, which enrolled an all-comer population of patients with mCRPC. So, at a median follow-up of around 53 months, in the intention-to-treat population, the combination of talazoparib plus enzalutamide significantly reduced the risk of death by 20% compared to enzalutamide alone, with a median OS of 45.8 months in the experimental arm versus 37 months in the control arm, which was an active control arm of enzalutamide. This improvement was consistent in patients with HRR alterations with a hazard ratio of 0.54 and in those with non-deficient or unknown HRR status, with a hazard ratio of 0.87. In a post hoc analysis, the hazard ratio for OS was 0.78 favoring the combination in those patients who did not have any HRR gene alteration in their tumors by both tissue and ctDNA testing. Consistent with the primary analysis, the updated rPFS data also favored the experimental arm with a median rPFS of 33.1 compared to 19.5 months in the control arm, and a hazard ratio of 0.667. No new safety signals were identified with extended follow-up. Thus, TALAPRO-2 is the first PARP inhibitor plus ARPI study to show a statistically significant and a clinically meaningful improvement in OS compared to standard-of-care enzalutamide as first-line treatment in patients with mCRPC unselected for HRR gene alterations. Dr. Peter Hoskin: Thank you, Neeraj. That's a great summary of the data presented and very important data indeed. There was another abstract also featured in the same session, Abstract 20, titled “Which patients with metastatic hormone-sensitive prostate cancer benefit more from androgen receptor pathway inhibitors? STOPCAP meta-analyses of individual participant data.” Neeraj, could you tell us more about this abstract? Dr. Neeraj Agarwal: Absolutely, I would be delighted to. So, in this meta-analysis, Dr. David Fischer and colleagues pooled individual participant data from different randomized phase 3 trials in the mHSPC setting to assess the potential ARPI effect modifiers and determine who benefits more from an ARPI plus ADT doublet. The primary outcome was OS for main effects and PFS for subgroup analyses. Prostate cancer specific survival was a sensitivity outcome. The investigators pooled data from 11 ARPI trials and more than 11,000 patients. Overall, there was a clear benefit of adding an ARPI on both OS and PFS, with hazard ratios of 0.66 and 0.51, respectively, representing a 13% and 21% absolute improvement at 5 years, respectively, with no clear difference by the class of agent. When stratifying the patients by age group, the effects of adding an ARPI on OS and PFS were slightly smaller in patients older than 75, than in those younger than 65, or aged between 65 and 75 years. Notably, in the trials assessing the use of abiraterone, we saw very little OS effects in the group of patients older than 75, however there was some benefit maintained in prostate-cancer specific survival, suggesting that other causes of death may be having an impact. The effects of the other ARPIs, or ‘lutamides' as I would call them, were similar across all three age subgroups on both OS and PFS. Therefore, the majority of patients with mHSPC benefit from the addition of ARPIs, and the benefits/risks of abiraterone and other ‘amides' must be considered in older patients.  Dr. Peter Hoskin: Thanks, Neeraj. Another great summary relevant to our day-to-day practice. Of course, there's ongoing collection of individual patient data from other key trials, which will allow robust comparison of ARPI doublet with triplet therapy (including docetaxel), guiding more personalized treatment.   Dr. Neeraj Agarwal: I agree with you, Peter, we need more data to help guide personalized treatment for patients with mHSPC and potentially guide de-escalation versus escalation strategies. Now, moving on to a different setting in prostate cancer, would you like to mention Abstract 17 titled, “Overall survival and quality of life with Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901),” presented by Dr. Louise Emmett? Dr. Peter Hoskin: Of course I will. So, ENZA-p was a multicenter, open-label, randomized, phase 2 trial conducted in Australia. It randomized 163 patients into adaptive doses (2 or 4 cycles) of Lu-PSMA-617 plus enzalutamide versus enzalutamide alone as first-line treatment in PSMA-PET-CT-positive, poor-risk, mCRPC. The interim analysis of ENZA-p with median follow-up 20 months showed improved PSA-progression-free survival with the addition of Lu-PSMA-617 to enzalutamide. Here, the investigators reported the secondary outcomes, overall survival, and health-related quality of life (HRQOL). After a median follow up of 34 months, overall survival was longer in the combination arm compared to the enzalutamide arm, with a median OS of 34 months compared to 26 months; with an HR of 0.55. Moreover, the combination improved both deterioration-free survival and health-related quality of life indicators for pain, fatigue, physical function, and overall health and quality of life compared to the control arm. Consistent with the primary analysis, the rPFS also favored the experimental arm with a median rPFS of 17 months compared to 14 months with a HR of 0.61. So, the addition of LuPSMA improved overall survival, and HRQOL in patients with high-risk mCRPC. Dr. Neeraj Agarwal: Thank you, Peter. Great summary, and promising results with Lu-177 and ARPI combination in first line treatment for mCRPC among patients who had two or more high risk features associated with early enzalutamide failure. Before we move on to bladder cancer, would you like to tell us about Abstract 15 titled, “World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration,” presented by Dr. Chad Tang?  Dr. Peter Hoskin: Sure. So, with metastatic-directed therapy (MDT), we have a number of phase 2 studies making up the database, and the X-MET collaboration aimed to consolidate all randomized data on oligometastatic solid tumors. This abstract presented pooled individual patient data from all the published trials involving patients with oligometastatic prostate cancer who received MDT alongside standard of care (SOC) against SOC alone. The analysis included data from five trials, encompassing 472 patients with oligometastatic prostate cancer, and followed for a median of 41 months. Patients were randomly assigned in a 1:1 ratio to receive either MDT plus SOC or SOC alone. The addition of MDT significantly improved PFS. The median PFS was 32 months with MDT compared to 14.9 months with SOC alone, with an HR of 0.45. Subgroup analyses further confirmed the consistent benefits of MDT across different patient groups. Regardless of factors like castration status, receipt of prior primary treatment, stage, or number of metastases, MDT consistently improved PFS. In patients with mHSPC, MDT significantly delayed the time to castration resistance by nine months, extending it to a median of 72 months compared to 63 months in the SOC group with an HR of 0.58. In terms of OS, the addition of MDT improved the 48-month survival rate by 12%, with OS rates of 87% in the MDT+SOC group compared to 75% in the SOC alone group. Dr. Neeraj Agarwal: Thank you, Peter. These data demonstrate that adding MDT to systemic therapy significantly improves PFS, rPFS, and castration resistance-free survival, reinforcing its potential role in the treatment of oligometastatic prostate cancer. So, let's switch gears to bladder cancer and start with Abstract 658 reporting the OS analysis of the CheckMate-274 trial. Would you like to tell us about this abstract?  Dr. Peter Hoskin: Yes, sure, Neeraj. This was presented by Dr. Matt Milowsky, and it was additional efficacy outcomes, including overall survival, from the CheckMate-274 trial which evaluated adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive bladder cancer after radical surgery. The phase 3 trial previously demonstrated a significant improvement in disease-free survival with nivolumab. With a median follow-up of 36.1 months, disease-free survival was longer with nivolumab compared to placebo across all patients with muscle-invasive bladder cancer, reducing the risk of disease recurrence or death by 37%. Among patients who had received prior neoadjuvant cisplatin-based chemotherapy, nivolumab reduced this risk by 42%, whilst in those who had not received chemotherapy, the risk was reduced by 31%. Overall survival also favored nivolumab over placebo, reducing the risk of death by 30% in all patients with muscle-invasive bladder cancer and by 52% in those with tumors expressing PD-L1 at 1% or higher. Among patients who had received prior neoadjuvant chemotherapy, nivolumab reduced the risk of death by 26%, whilst in those who had not received chemotherapy, the risk was reduced by 33%. Alongside this, the safety profile remained consistent with previous findings. Dr. Neeraj Agarwal: Thank you, Peter, for such a nice overview of this abstract. These results reinforce adjuvant nivolumab as a standard of care for high-risk muscle-invasive bladder cancer, offering the potential for a curative outcome for our patients. Dr. Peter Hoskin: I agree with you Neeraj. Perhaps you would like to mention Abstract 659 titled, “Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.” Dr. Neeraj Agarwal: Of course. Dr. Galsky presented additional outcomes from the phase 3 NIAGARA study, which evaluated perioperative durvalumab combined with neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. The study previously demonstrated a significant improvement in event-free survival and overall survival with durvalumab compared to chemotherapy alone, with a manageable safety profile and no negative impact on the ability to undergo radical cystectomy. Among the 1,063 randomized patients, those who received durvalumab had a 33% reduction in the risk of developing distant metastases or death and a 31% reduction in the risk of dying from bladder cancer compared to those who received chemotherapy alone. More patients who received durvalumab achieved a pathological complete response at the time of surgery with 37% compared to 28% in the chemotherapy-alone group. Patients who achieved a pathological complete response had better event-free survival and overall survival compared to those who did not. In both groups, durvalumab provided additional survival benefits, reducing the risk of disease progression or death by 42% and the risk of death by 28% in patients with a pathological complete response, while in those patients without a pathological complete response, the risk of disease progression or death was reduced by 23% and the risk of death by 16% when durvalumab was added to the chemotherapy. Immune-mediated adverse events occurred in 21% of patients in the durvalumab group compared to 3% in the chemotherapy-alone group, with grade 3 or higher events occurring in 3% compared to 0.2%. The most common immune-related adverse events included hypothyroidism in 10% of patients treated with durvalumab compared to 1% in the chemotherapy-alone group, and hyperthyroidism in 3% versus 0.8%. At the time of the data cutoff, these adverse events had resolved in 41% of affected patients in the durvalumab group and 44% in the chemotherapy-alone group. Dr. Peter Hoskin: Thank you, Neeraj, for the great summary. These findings further support the role of perioperative durvalumab as a potential standard of care for patients with muscle-invasive bladder cancer. Dr. Neeraj Agarwal: I concur with your thoughts, Peter. Before wrapping up the bladder cancer section, would you like to mention Abstract 664 reporting updated results from the EV-302 trial, which evaluated enfortumab vedotin in combination with pembrolizumab compared to chemotherapy as first-line treatment for patients with previously untreated locally advanced or metastatic urothelial carcinoma? Dr. Peter Hoskin: Yes, of course. Dr. Tom Powles presented updated findings from the EV-302 study, and in this abstract presented 12 months of additional follow-up for EV-302 (>2 y of median follow-up) and an exploratory analysis of patients with confirmed complete response (cCR). The study had a median follow-up of 29.1 months and previously demonstrated significant improvements in progression-free survival and overall survival with enfortumab vedotin and pembrolizumab. This is now the standard of care in global treatment guidelines. Among the 886 randomized patients, enfortumab vedotin and pembrolizumab reduced the risk of disease progression or death by 52% and the risk of death by 49% compared to chemotherapy. The survival benefit was consistent regardless of cisplatin eligibility or the presence of liver metastases. The confirmed objective response rate was higher with enfortumab vedotin and pembrolizumab at 67.5% compared to 44.2% with chemotherapy. The median duration of response was 23.3 months with enfortumab vedotin and pembrolizumab compared to 7.0 months with chemotherapy. A complete response was achieved in 30.4% of patients in the enfortumab vedotin and pembrolizumab group compared to 14.5% in the chemotherapy group, with the median duration of complete response not yet reached in the enfortumab vedotin and pembrolizumab group compared to 15.2 months in the chemotherapy group. Severe treatment-related adverse events occurred in 57.3% of patients treated with enfortumab vedotin and pembrolizumab compared to 69.5% in the chemotherapy group, while in patients who achieved a complete response, severe adverse events occurred in 61.7% of those treated with enfortumab vedotin and pembrolizumab compared to 71.9% with chemotherapy. Treatment-related deaths were reported in 1.1% of patients treated with enfortumab vedotin and pembrolizumab compared to 0.9% with chemotherapy, with no treatment-related deaths occurring in those who achieved a complete response. These findings clearly confirm the durable efficacy of enfortumab vedotin and pembrolizumab, reinforcing its role as the standard of care for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma, and no new safety concerns have been identified. Dr. Neeraj Agarwal: Thank you for this great summary. Moving on to kidney cancer, let's talk about Abstract 439 titled, “Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate-9ER trial.” Dr. Peter Hoskin: Sure. Dr. Motzer presented the final results from the phase 3 CheckMate-9ER trial, which compared the combination of cabozantinib and nivolumab against sunitinib in previously untreated advanced renal cell carcinoma. The data after more than five years follow-up show that the combination therapy provided sustained superior efficacy compared to sunitinib. In terms of overall survival, we see an 11-month improvement in median OS, 46.5 months for the cabo-nivo versus 35.5 months for sunitinib and a 42% reduction in the risk of disease progression or death, with median progression-free survival nearly doubling – that's 16.4 months in the combination group and 8.3 months with sunitinib. Importantly, the safety profile was consistent with the known safety profiles of the individual medicines, with no new safety concerns identified. Dr. Neeraj Agarwal: Great summary, Peter. These data further support the efficacy of cabo-nivo combination therapy in advanced renal cell carcinoma, which is showing a 11-month difference in overall survival. Dr. Peter Hoskin: Neeraj, before wrapping up this podcast, would you like to tell us about Abstract 618? This is titled “Prospective COTRIMS (Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma) trial: Final results.” Dr. Neeraj Agarwal: Sure, Peter. I would be delighted to. Dr Heidenrich from the University of Cologne in Germany presented the COTRIMS data evaluating retroperitoneal LN dissection in patients with clinical stage 2A/B seminomas. Seminomas are classified as 2A or B when the disease spreads to the retroperitoneal lymph nodes of up to 2 cm (CS IIA) or of more than 2 cm to up to 5 cm (CS 2B) in maximum diameter, respectively. They account for 10-15% of seminomas and they are usually treated with radiation and chemotherapy. However, radiation and chemo can be associated with long-term toxicities such as cardiovascular toxicities, diabetes, solid cancers, leukemia, particularly for younger patients. From this standpoint, Dr Heidenrich and colleagues evaluated unilateral, modified template, nerve-sparing retroperitoneal lymph node dissection as a less toxic alternative compared to chemo and radiation. They included 34 patients with negative AFP, beta-HCG, and clinical stage 2A/B seminomas. At a median follow-up of 43.2 months, the trial demonstrated great outcomes: a 99.3% treatment-free survival rate and 100% overall survival, with only four relapses. Antegrade ejaculation was preserved in 88% of patients, and severe complications such as grade 3 and 4 were observed in 12% of patients. Pathological analysis revealed metastatic seminoma in 85% of cases, with miR371 being true positive in 23 out of 24 cases and true negative in 100% of cases. It appears to be a valid biomarker for predicting the presence of lymph node metastases. These findings highlight retroperitoneal lymph node dissection is feasible; it has low morbidity, and excellent oncologic outcomes, avoiding overtreatment in 80% of patients and sparing unnecessary chemotherapy or radiotherapy in 10-15% of cases. Dr. Peter Hoskin: Great summary and important data on retroperitoneal lymphadenectomy in metastatic seminoma. These findings will help shape clinical practice. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Before wrapping up this podcast, I would like to say that we have reviewed several abstracts addressing prostate, bladder, kidney cancers, and seminoma, which are impacting our medical practices now and in the near future. Peter, thank you for sharing your insights with us today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion and your leadership of the conference. Many thanks. Dr. Peter Hoskin: Thank you, Neeraj. Thank you for the opportunity to share this information more widely. I'm aware that whilst we have nearly 6,000 delegates, there are many other tens of thousands of colleagues around the world who need to have access to this information. And it was a great privilege to chair this ASCO GU25. So, thank you once again, Neeraj, for this opportunity to share more of this information that we discussed over those few days. Dr. Neeraj Agarwal: Thank you, Peter. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:   Dr. Neeraj Agarwal    @neerajaiims    Dr. Peter Hoskin Follow ASCO on social media:      @ASCO on Twitter      ASCO on Bluesky  ASCO on Facebook      ASCO on LinkedIn      Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Peter Hoskin: Research Funding (Institution): Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta, Bristol Myers  

Dave becomes acquainted with Dr. Kim Byas, who, among his several current endeavors, including Vice President of Community Engagement and Impact at The Center for Health Affairs, is a member of the Conscious Leadership Guild. In the course of this conversation, Kim introduces the concept of the origin story. Each of us has one, yet to inform and grow our practices, we can become more aware of this unique personal resource. Journaling is one way of doing so. 

Send us a textIn this captivating episode, Joey Pinz sits down with communication expert Amanda Kenderes, who unveils her groundbreaking model of three "Talk Types" that define how we interact with one another. Amanda breaks down the "A," "B," and "C" communication styles—Informing, Relating, and Meeting Makers—into a simple framework that anyone can use to better understand themselves and those around them.

Today, we're joined by Emad Mostaque, an innovative leader in the AI field and founder of Shelling AiH. In this episode, we delve deep into the intricacies of artificial intelligence, exploring its immense potential as well as the challenges and ethical dilemmas it poses. Tom and Emad discuss the critical aspects of AI control, the risk of subtle manipulation, and the importance of decentralized and open-source models. They investigate how AI can transform sectors like education, healthcare, and governance, while also addressing concerns about autonomy, transparency, and societal impacts. Join us as we navigate the philosophical and practical dimensions of AI's role in our future, examining everything from economic disruptions to the potential reshaping of democracy, and the very nature of work and human fulfillment. This discussion is packed with insights, thought-provoking questions, and forward-thinking solutions that you won't want to miss. SHOWNOTES 00:00 China's geostrategic impact more concerning than AI. 07:03 Digital control to change Hollywood employment landscape. 13:41 Talk show hosts influence public opinion, political change. 18:46 Informing citizens enhances representation in democratic processes. 24:49 Tech enables democracy, transparency; builds personal defenses. 28:42 New AI models excel in complex tasks. 33:42 Increasing compute leads to internal AI politics. 41:24 AI trust issues, governance, open-source data needed. 45:24 Computers build usable AI models for collaboration. 50:14 Open source AI systems need customizable governance. 55:52 China may use AI for invasive surveillance. 01:03:24 AI governance threatens individual privacy and control. 01:08:57 Purpose and happiness intertwine, balancing freedoms' concepts. 01:13:16 Design systems to enhance human agency, capability. 01:20:17 Coordination needed for food, education, resources globally. 01:26:34 Success is valued through personal achievement and progress. 01:28:27 Overcame illness, wrote reflective book on life. CHECK OUT OUR SPONSORS Range Rover: Explore the Range Rover Sport at  https://landroverUSA.com Oracle: Take a free test drive of OCI at https://oracle.com/theory Shopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impact Momentous: Shop now at https://livemomentous.com and use code IMPACT for 20% your new Momentous routine. FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu What's up, everybody? It's Tom Bilyeu here. If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. LISTEN AD FREE + BONUS EPISODES on APPLE PODCASTS: apple.co/impacttheory Learn more about your ad choices. Visit megaphone.fm/adchoices